Literature DB >> 17920711

Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist.

Anthony J White, Andre LaGerche, Guy C Toner, Robert J Whitbourn.   

Abstract

Apical ballooning syndrome (ABS) describes acute regional myocardial dysfunction and has a strong association with emotional stress and female sex. Whilst catecholamine excess has been described in this condition, the precise etiology remains elusive. We report the atypical case of a 61 year old male who developed ABS in the absence of a clear precipitant. His concurrent treatment with a vascular endothelial growth factor (VEGF) receptor antagonist may provide an insight into the pathogenesis of this enigmatic condition. We present a biologically plausible explanation as to why VEGF antagonism may have an important role through its modulation of nitric oxide and catecholamine effects. This hypothesis may also provide an important insight into the cardiovascular toxicities associated with this class of drug. In addition, we report the success of treatment with a beta blocker in ABS complicated by a severe left ventricular outflow tract obstruction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920711     DOI: 10.1016/j.ijcard.2007.07.066

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.

Authors:  Behrooz K Shamloo; Pankdeep Chhabra; Andrew N Freedman; Arnold Potosky; Jennifer Malin; Sheila Weiss Smith
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

Review 2.  Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.

Authors:  Sidney V Keisner; Sachin R Shah
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

3.  Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development.

Authors:  Daniel Pinkhas; Thai Ho; Sakima Smith
Journal:  Cardiooncology       Date:  2017-06-30

4.  Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects.

Authors:  Sarah Hamidi; Andrée Boucher; Bernard Lemieux; Geneviève Rondeau; Rebecca Lebœuf; Louis-Georges Ste-Marie; Xuan Kim Le; Hortensia Mircescu
Journal:  J Endocr Soc       Date:  2022-03-23

Review 5.  Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.

Authors:  Young Kwang Chae; Lauren Chiec; Scott K Adney; Josh Waitzman; Ricardo Costa; Benedito Carneiro; Maria Matsangou; Mark Agulnik; Peter Kopp; Frank Giles
Journal:  Oncotarget       Date:  2018-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.